- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 15.07. | GSK telegraphs 'very limited number' of job cuts amid R&D investment spree | ||
| 15.07. | HHS terminates employees after Supreme Court allows reduction in force to proceed | ||
| 15.07. | Sellas' CDK9 inhibitor tied to 50% response rate in certain AML patients in phase 2 study | ||
| 15.07. | Sino Biopharm buys Merck's PD-1xVEGF bispecific partner LaNova for up to $951M | ||
| 15.07. | Hengrui's GLP-1/GIP agonist reports 18% weight loss in phase 3 trial, readies China push | ||
| 15.07. | Acumen taps JCR's blood-brain barrier tech for $555M Alzheimer's deal | ||
| 14.07. | China biotechs 'reshaping' US biopharma as outlicensing deals rise 11%: Jefferies report | ||
| 14.07. | Merck wades deeper into HIV PrEP waters dominated by Gilead with 2 new late-stage trials | ||
| 14.07. | Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal | ||
| 14.07. | Takeda's narcolepsy blockbuster hopeful secures double phase 3 wins, teeing up FDA filing | ||
| 14.07. | AstraZeneca's $1.3B bet on CinCor's blood pressure med appears to pay off with phase 3 win | ||
| 11.07. | Relmada terminates license agreement for troubled phase 3 depression asset | ||
| 11.07. | Karyopharm lays off more workers as hunt for strategic alternatives turns up short | ||
| 11.07. | FDA rejects Capricor's DMD cell therapy, asks for more data | ||
| 10.07. | FDA releases 'initial batch' of more than 200 drug rejection letters | ||
| 10.07. | Eolas regains opioid use disorder drug abandoned by AstraZeneca | ||
| 10.07. | AbbVie pays $700M upfront for trispecific rival to J&J, Pfizer in blood cancer | ||
| 10.07. | Lack of early win for Ultragenyx, Mereo's bone disorder med dents stock, but analysts keep faith | ||
| 10.07. | Radiopharma biotech raises $99M series B to test copper-based diagnostic, therapeutic combo | ||
| 09.07. | Revolution lines up Iambic's AI platform in discovery collab worth up to $25M | ||
| 09.07. | Veteran venture capitalists launch new firm to Vie for autoimmune success | ||
| 09.07. | Novartis inks $175M option deal for Sironax's blood-brain barrier tech | ||
| 09.07. | Rhythm's phase 2 obesity pill trial hits primary endpoint, sending stock up | ||
| 09.07. | Jasper halves workforce after dud drug surprise, narrows R&D focus | ||
| 09.07. | AstraZeneca's Alexion strengthens gene therapy offering with $825M AAV capsid pact |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .